More importantly, increasing evidence has documented that HDAC inhibitors improve radiosensibility in malignancies, including lung cancer, colon cancer, glioma and squamous cell carcinoma [28–31], suggesting the implication of HDACs in tumor radiation resistance. The gene discussed is HDAC9; the disease is lung carcinoma.